Mechanisms of VEGF (receptor) inhibitors-induced cardiovascular complications
Schematic diagram of the mechanisms of VEGF (receptor) inhibitors-induced cardiovascular complications. Inhibiting the PI3K/Akt pathway causes apoptosis to be activated and ROS to accumulate, which may harm mitochondrial function. Whereas, blocking off-target kinases such as AMPK is linked to disrupting energy homeostasis, decreased cell survival, and a reduced ability to respond to cardiac stress. Each element might have an impact on how HF develops. When it comes to artery thrombosis, the lowered level of PGI2 and NO encourages platelet aggregation, and the level of TXA2 is elevated, which predisposes an individual to ATEs. Furthermore, oxidative stress may result from reduced NO production. Additionally, compromised vascular integrity could root in antiangiogenesis and lead to thrombosis. To sum up, hypertension, cardiac dysfunction, and ATEs are brought on by VEGF (receptor) suppression. AMPK, adenosine 5′-monophosphate-activated protein kinase; ATE, arterial thromboembolic event; NO, nitric oxide; PGI2, prostacyclin; ROS, reactive oxygen species; TKIs, tyrosine kinase inhibitors; TXA2, thromboxane A2; VEGF, vascular endothelial growth factor
Publication
Cardiovascular Complications of Pan-Cancer Therapies: The Need for Cardio-Oncology (2023) Mengjia Chen, et al. Cancers (Basel). 2023 Jun;15(11). Figure: F1.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | VEGF-A | VEGFA | ncbigene_symbol | VEGFA | 7422 |
| Homo sapiens | Primates | VEGF-B | VEGFB | ncbigene_symbol | VEGFB | 7423 |
| Homo sapiens | Primates | VEGF-C | VEGFC | ncbigene_symbol | VEGFC | 7424 |
| Homo sapiens | Primates | VEGF-D | VEGF-D | ncbigene_synonym | VEGFD | 2277 |
| Homo sapiens | Primates | PTK | PTK | ncbigene_synonym | PTK2B | 2185 |
| Homo sapiens | Primates | TK | TK | famplex_relations | TK1 | 7083 |
| Homo sapiens | Primates | TK | TK | famplex_relations | TK2 | 7084 |
| Homo sapiens | Primates | VEGFR-2 | VEGFR2 | ncbigene_synonym | KDR | 3791 |
| Homo sapiens | Primates | VEGFR-3 | VEGFR-3 | ncbigene_synonym | FLT4 | 2324 |
| Homo sapiens | Primates | VEGFR-1 | VEGFR-1 | ncbigene_synonym | FLT1 | 2321 |
| Homo sapiens | Primates | PI3K | PI3K | ncbigene_synonym | PIK3CA | 5290 |
| Homo sapiens | Primates | PI3K | PI3K | ncbigene_synonym | PIK3CB | 5291 |
| Homo sapiens | Primates | PI3K | PI3K | ncbigene_synonym | PIK3CD | 5293 |
| Homo sapiens | Primates | PI3K | PI3K | ncbigene_synonym | PIK3CG | 5294 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R3 | 8503 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R4 | 30849 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R5 | 23533 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R6 | 146850 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R1 | 5295 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R2 | 5296 |
| Homo sapiens | Primates | PLCY | PLCG | famplex_relations | PLCG1 | 5335 |
| Homo sapiens | Primates | PLCY | PLCG | famplex_relations | PLCG2 | 5336 |
| Word | Match | MeSH | Name | ChEBI |
|---|---|---|---|---|
| Sunitinib | sunitinib | N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide | chebi:38940 | |
| Sorafenib | sorafenib | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide | chebi:50924 | |
| pazopanib | pazopanib | 5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide | chebi:71219 | |
| Axitinib | axitinib | N-methyl-2-({3-[(E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide | chebi:66910 |
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|---|---|---|---|
| Hypertension | hypertension | hypertension | DOID:10763 |